Trifluoroacetic acid → 2-Amino-1-{5-[4-(benzothiazol-2-yloxy)-benzyl]-hexahydro-pyrrolo[3,4-b]pyrrol-1-yl}-ethanone
反応式
Cl.[NH:2]1[CH2:6][CH2:5][CH:4]2[CH2:7][N:8]([CH2:10][C:11]3[CH:26]=[CH:25][C:14]([O:15][C:16]4[S:17][C:18]5[CH:24]=[CH:23][CH:22]=[CH:21][C:19]=5[N:20]=4)=[CH:13][CH:12]=3)[CH2:9][CH:3]12.CCN(CC)CC.C([NH:41][CH2:42][C:43](O)=[O:44])(OC(C)(C)C)=O.Cl.CN(C)CCCN=C=NCC.FC(F)(F)C(O)=O>C(Cl)Cl.CO.CS(C)=O>[NH2:41][CH2:42][C:43]([N:2]1[CH2:6][CH2:5][CH:4]2[CH2:7][N:8]([CH2:10][C:11]3[CH:26]=[CH:25][C:14]([O:15][C:16]4[S:17][C:18]5[CH:24]=[CH:23][CH:22]=[CH:21][C:19]=5[N:20]=4)=[CH:13][CH:12]=3)[CH2:9][CH:3]12)=[O:44]参加物
反応物 5
生成物 1
試薬・触媒・溶媒 2
実験手順
To a stirred solution of 2-[4-(hexahydro-pyrrolo[3,4-b]pyrrol-5-ylmethyl)-phenoxy]-benzothiazole hydrochloride (100 mg, 0.26 mmol) and Et3N (215 μL, 1.6 mmol) in CH2Cl2 (2 mL) was added N-Boc-glycine (95 mg, 0.5 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (104 mg, 0.5 mmol). The resulting solution was then stirred at rt for 16 h. The resulting mixture was then treated with trifluoroacetic acid (1 mL) at rt for 3 h. The crude solid was dissolved in CH3OH/DMSO (2:1) and purified via reverse phase preparative HPLC to yield the title compound as a fluffy white solid (37 mg, 35%). MS (ESI): mass calcd. for C22H24N4O2S, 408.5; m/z found, 409.2 [M+H]+. 1H NMR (500 MHz, CDCl3): 7.74 (d, J=8.1 Hz, 1H), 7.68 (d, J=8.0 Hz, 1H), 7.43-7.33 (m, 3H), 7.33-7.26 (m, 3H), 4.51-4.42 (m, 1H), 4.27-4.19 (m, 0.5H), 4.02-3.92 (m, 0.5H), 3.66 (d, J=13.2 Hz, 1H), 3.58 (d, J=5.0 Hz, 0.5H), 3.51-3.37 (m, 3H), 3.28 (d, J=16.7 Hz, 0.5H), 2.91-2.76 (m, 2H), 2.70-2.60 (m, 1H), 2.58-2.50 (m, 1H), 2.50-2.37 (m, 1H), 2.14-1.96 (m, 1H), 1.97-1.80 (m, 1H).
後処理
- custompurified via reverse phase preparative HPLC
出典と根拠
- ORDレコード
- ord-5f25c30a6dd84138ac01f6d28f24a464
- 出典データセット
- uspto-grants-2011_05
- 特許番号
- US07935725B2
反応ノート
読み込み中…